Novavax Inc (NVAX), a clinical-stage vaccine company, on Tuesday said it plans a $175 million underwritten public offering of its common stock.
Novavax also intends to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of its common stock.
The company expects to use the net proceeds from the offering for the advancement of its lead vaccine candidates and general corporate purposes, including acquisitions.
J.P. Morgan and Citigroup are acting as joint book-running managers of the offering.
Novavax shares were down 4.7% at $8.82 in after-hours trade on the Nasdq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.